Publications (502) María Victoria Mateos Manteca publications


  1. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

    Haematologica, Vol. 109, Núm. 3, pp. 867-876

  2. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  3. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 4, pp. 224-231.e2

  4. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

  5. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

  6. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

    Blood Advances, Vol. 8, Núm. 2, pp. 388-398

  7. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study

    Haematologica, Vol. 109, Núm. 3, pp. 895-905

  8. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial

    European Journal of Haematology

  9. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

    Cancer, Vol. 130, Núm. 6, pp. 886-900

  10. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  11. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study

    European Journal of Haematology, Vol. 112, Núm. 3, pp. 402-411

  12. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  13. Prevalence and Consequences of a Delayed Diagnosis in Multiple Myeloma: A Single Institution Experience

    Clinical Lymphoma, Myeloma and Leukemia

  14. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

    Haematologica, Vol. 109, Núm. 3, pp. 877-887

  15. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 6, pp. 358-363

  16. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

  17. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma


  18. Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma

    Clinical Cancer Research

  19. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

  20. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

    Blood Advances, Vol. 8, Núm. 1, pp. 194-206